[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atherosclerosis-of-artery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atherosclerosis-of-artery":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,77,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100523107","florbetaben-for-imaging-of-vascular-amyloid-100523107",false,"NCT06091319","Florbetaben for Imaging of Vascular Amyloid","Florbetaben for Imaging of Vascular Amyloid: Evaluation of Amyloid Inflammasome Imaging in Carotid and Coronary Arteries in Patients With Unstable Atherosclerosis- A Pilot Study","FERMATA","Inclusion Criteria:\n\n1. suffered a recent cardiovascular event (30-120 days post ACS (i.e. STEMI or NSTEMI) or TIA\u002Fstroke with ipsilateral large vessel atherosclerotic disease confirmed on US, CT or MRI;\n2. stable symptoms and hemodynamics;\n3. age \\>\u002F= 18 years;\n4. given informed consent.\n\nExclusion Criteria:\n\n1. a recent CV event likely to have been embolic in the opinion of the neurologist or cardiologist;\n2. severe LV dysfunction (EF\\\u003C30%);\n3. severe valve disease requiring intervention;\n4. decompensated heart failure;\n5. pregnancy (all women of child bearing potential will have a negative BHCG test;\n6. breastfeeding;\n7. women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception;.\n8. unable to give informed consent;.\n9. Florbetaben allergy;\n10. glomerular filtration rate (GFR) \\\u003C50 ml\u002Fmin\u002F1.72m2\n\nExclusion for CTA portion of the protocol: Patients with dye allergy, or those with GFR \\\u003C60, will not undergo CTA but will have PET\u002FCT.",true,"ALL","18 Years",{"count":21,"type":22},30,"ESTIMATED","OBSERVATIONAL","The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke\u002FTIA.",[26,27,28,29],"Acute Coronary Syndrome","Stroke","Transient Ischemic Attack","Atherosclerosis of Artery","RECRUITING","2026-05-05",{"date":33,"type":34},"2026-05-08","ACTUAL",{"date":36,"type":34},"2023-10-09",{"date":38,"type":22},"2026-08-01",{"name":40,"class":41},"Ottawa Heart Institute Research Corporation","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":53,"studyType":23,"phases":4,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":42},"100615773","oral-microbiome-in-carotid-atherosclerosis-100615773","NCT07296965","Oral Microbiome in Carotid Atherosclerosis","The Role of the Oral Microbiome in Carotid Atherosclerosis: Investigating in a Cross-sectional Study the Microbial Influence on Plaque Development and Vulnerability Based on Biobank Data","OMICA","Inclusion Criteria:\n\n* Confirmed internal carotid artery (ICA) stenosis on preoperative photon-counting computed tomography (CTA)\n* Adults (≥18 years) undergoing carotid endarterectomy at Semmelweis University.\n* Eligible for surgery based on standard anesthesiologic evaluation.\n* Willing and able to provide written informed consent for participation and sample collection.\n\nExclusion Criteria:\n\n* Active systemic infection or current antibiotic therapy within 30 days before surgery.\n* Immunosuppressive therapy or immunodeficiency disorders.\n* Inability to undergo MRI (e.g., pacemaker, metallic implants, severe claustrophobia).\n* Pregnancy or lactation.\n* Malignancy under active treatment.\n* Prior carotid surgery or stenting on the same side.\n* Refusal or inability to provide informed consent.",{"count":52,"type":22},200,"1 Year","The goal of this observational study, called OMICA (Oral Microbiome in Carotid Atherosclerosis), is to learn how bacteria living in the mouth may influence the development and stability of plaques in the carotid arteries, which supply blood to the brain. Plaque buildup in these arteries can lead to stroke.\n\nResearchers want to understand whether certain oral bacteria are linked to plaque vulnerability, meaning a higher chance that the plaque will rupture and cause a stroke.\n\nThe study will include a cohort of adults scheduled for carotid endarterectomy at Semmelweis University. Participants will be enrolled in the Semmelweis University Carotid Biobank project.\n\nThe main questions the study aims to answer are:\n\nDo people with more severe gum disease or tooth infection have a higher number of bacteria in their carotid plaques, and are those plaques more likely to rupture?\n\nAre the bacteria found in vulnerable plaques different from those in stable plaques?\n\nAre similar bacteria found in the mouth, gut, and plaques, suggesting that bacteria may travel through the body?\n\nWhat participants will do:\n\nHave their oral health checked before surgery, including an exam of gum disease and tooth infections.\n\nProvide microbiome samples from the mouth, anus, urine, and carotid plaque (taken during surgery).\n\nHave preoperative photon-counting computed tomography (CT) performed to assess plaque stability and study eligibility.\n\nAll samples and imaging data will be analyzed to identify bacterial species and their relationship to plaque type.\n\nThe study does not involve any experimental treatment or medication. Participation adds no significant medical risk beyond standard care.\n\nResearchers will compare bacterial patterns between people with vulnerable plaques and those with stable plaques to identify microbial signatures linked to carotid plaque instability.\n\nThe results may help create future microbiome-based risk models for detecting people at higher risk of stroke or severe atherosclerosis.",[56,29,57,58,59],"Atherosclerosis Cardiovascular Disease","Carotid Artery Plaque","Periodontitis","Carotid Artery Diseases",[61,62,63,64,65,66,67],"Oral Microbiome","Carotid Plaque","Plaque vulnerability","Atherosclerosis","Periodontal disease","Biobank study","Microbial colonization","2026-04-21",{"date":70,"type":34},"2026-04-22",{"date":72,"type":34},"2025-11-01",{"date":74,"type":22},"2029-11-01",{"name":76,"class":41},"Semmelweis University Heart and Vascular Center",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":97,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100550486","phase-3-interleukin-6-receptor-inhibition-for-symptomatic-intracranial-atherosclerosis-100550486","NCT06447701","Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis","Effect of Interleukin-6 Receptor Inhibition for Avoiding Recurrence of Ischemic Stroke in Patients With Symptomatic Intracranial Atherosclerosis: a Double-blind, Randomized, Placebo-controlled Trial","IRIS-sICAS","Inclusion Criteria:\n\n* Male or non-pregnant women with acute stroke symptoms aged over 18 years.\n* Patients having an ischemic stroke or a TIA prior to randomization (Patients having an acute ischemic stroke within 72 hours with NIHSS score≤5 at baseline, or patients having a TIA within 72 hours with Oxfordshire Community Stroke Project on the basis of age, blood pressure, clinical features, and duration of TIA symptoms (ABCD2) score≥4 at baseline).\n* The entry event is attributed to symptomatic atherosclerosis (50-99%) in an intracranial qualifying artery (intracranial carotid artery (C4-7), middle cerebral artery (M1), intracranial vertebral artery or basilar artery) confirmed by CT, MR angiography, or digital subtraction angiography.\n* Informed consent obtained from patients or their legal representatives.\n* Willing to be followed up as required by the clinical study protocol.\n\nExclusion Criteria:\n\n* Thrombolytic therapy or thrombectomy within 24 hours prior to enrollment.\n* Pre-stroke mRS score ≥ 2.\n* Combined or previous intracranial hemorrhage: hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.\n* Any of the following unequivocal cardiac source of embolism: chronic or paroxysmal atrial fibrillation, sinus node dysfunction, mitral stenosis, prosthetic heart valves, endocarditis, left ventricular mural thrombus or valvular vegetation, myocardial infarction within three months, dilated cardiomyopathy, spontaneous echogenic defects in the left atrium or an ejection fraction of less than 30%.\n* Intracranial arterial stenosis due to arterial dissection, Moya Moya disease; herpes zoster, varicella zoster or other viral vasculopathy; neurosyphilis; radiation induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; post-partum angiopathy; suspected vasospastic process, suspected recanalized embolus; any known vasculitic disease.\n* Extracranial stenosis ≥50%, subclavian arterial stenosis≥50% or subclavian steal syndrome.\n* Previous interventions for intracranial arterial stenosis.\n* Concurrent intracranial tumors, intracranial aneurysms or arteriovenous malformations\n* Neutrophil \\\u003C 2×10 9\u002FL.\n* Platelet \\\u003C 100×10 9\u002FL.\n* Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 1.5 times the upper limit of normal.\n* Active infections including localized.\n* Evidence of HIV or hepatitis B positivity.\n* Positive tuberculosis-related tests.\n* Concurrent peptic ulcer, diverticulitis or inflammatory bowel disease.\n* Concurrent malignant tumors, recent bone marrow transplant or recent organ transplant.\n* Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg despite blood pressure control.\n* Known allergy to tocilizumab or excipients.\n* Use of immunosuppressive drugs or systemic use of antibiotics.\n* Received any live or live attenuated vaccine within 4 weeks prior to enrollment or plan to receive a live or live attenuated vaccine during the study.\n* History of demyelination or presence of neurological symptoms suggestive of demyelination.\n* Previously existing neurological or psychiatric disorders that could potentially confuse neurological function assessment.\n* An expected survival less than 90 days.\n* Participation in another interventional clinical study.\n* Patients unsuitable for enrollment in the clinical trial according to investigators decision making.",{"count":86,"type":22},486,"INTERVENTIONAL",[89],"PHASE3","IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in lowering the incidence of newly diagnosis ischemic stroke and improving prognosis in symptomatic intracranial atherosclerosis patients.",[92,93,94,27,95,29,96],"Brain Diseases","Ischemic Stroke","Ischemia","Cerebral Infarction","Atheroscleroses, Intracranial",[98,99,100,101],"Tocilizumab","Symptomatic intracranial atherosclerotic stenosis","Recurrence","Ischemic stroke","NOT_YET_RECRUITING","2025-07-24",{"date":105,"type":34},"2025-07-28",{"date":107,"type":22},"2025-10-30",{"date":109,"type":22},"2029-06-30",{"name":111,"class":41},"Zhujiang Hospital",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":42},"100562511","efficacy-of-probucol-combined-with-statins-treatment-for-ischemic-stroke-100562511","NCT06604117","Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke","A Prospective, Open-label Study Evaluating the Effects of Probucol Combined with Statins on Atherosclerotic Characteristics and Prognosis in Patients with Ischemic Stroke","EPCIS","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Diagnosed with ischemic stroke (IS) confirmed by cranial CT\u002FMRI.\n3. Onset of stroke within the last 30 days.\n4. Evidence of atherosclerosis (AS) in at least one artery (carotid, coronary, aorta, renal, or peripheral arteries) identified through neck CTA, coronary CTA, or ultrasound examination of lower extremity arteries.\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. History of allergy to Probucol or statins.\n2. Non-atherosclerotic arterial stenosis, such as vasculitis, moyamoya disease, or arterial dissection.\n3. Potential cardiac embolic sources, such as atrial fibrillation, artificial heart valves, endocarditis, or patent foramen ovale.\n4. Known bleeding tendencies or hemorrhagic diseases, such as thrombocytopenia (platelet count \\< 100 × 10\\^9\u002FL), hemorrhagic stroke, or gastrointestinal bleeding.\n5. Severe myocardial diseases such as myocardial infarction (MI) or myocarditis.\n6. Liver (ALT or AST \\> twice the upper limit of normal) or kidney (creatinine \\> 1.5 times the upper limit of normal or glomerular filtration rate \\< 50 ml\u002Fmin) dysfunction.\n7. Ventricular tachycardia, bradycardia, torsades de pointes, or syncopal episodes of cardiac origin.\n8. Prolonged QT interval or conditions that may prolong the QT interval, such as certain medications.\n9. Suffering from a severe illness with a life expectancy of less than one year or unable to cooperate due to cognitive or psychological issues.\n10. Use of Probucol or any lipid-lowering medication other than statins, ezetimibe, and PCSK9 inhibitors within the 30 days prior to enrollment, including bile acid sequestrants, fibrates, and other similar drugs.\n11. Pregnant or breastfeeding individuals, those trying to conceive.\n12. Concurrent participation in another clinical trial involving investigational drugs or devices within the past 30 days.\n13. Planned surgery or intervention that would require discontinuation of the study medication during the study period.\n14. Any reason, known to the participant and investigator, that would prevent the participant from adhering to the study protocol or follow-up.\n15. Other conditions determined by the investigator that may require exclusion.",{"count":52,"type":22},"The goal of this clinical trial is to evaluate whether the combination of Probucol with statin therapy can reduce the risk of vascular events and improve atherosclerosis outcomes in adults with ischemic stroke and confirmed atherosclerosis. The main questions it aims to answer are:\n\nDoes adding Probucol to statin therapy reduce plaque burden more effectively than statins alone? Does the combination therapy lead to fewer cardiovascular and cerebrovascular events compared to statins alone? Researchers will compare participants receiving standard statin therapy to those receiving statins combined with Probucol to assess differences in plaque burden and the occurrence of vascular events.\n\nParticipants will:\n\nChoose either standard statin therapy (with possible addition of ezetimibe or PCSK9 inhibitors) or the same therapy combined with Probucol 0.5g twice daily.\n\nAttend regular follow-up visits for monitoring atherosclerosis features and cardiovascular health over a 3-year period.\n\nUndergo imaging studies to evaluate changes in atherosclerosis and blood tests to monitor lipid levels and other biomarkers.",[93,29,123,124],"Lipid Disorder","Statin",[126,124,64,101,127,128],"Probucol","Plaque burden","Lipid-lowering treatment","2025-03-20",{"date":131,"type":34},"2025-03-25",{"date":133,"type":34},"2024-10-17",{"date":135,"type":22},"2027-10",{"name":137,"class":41},"Xuanwu Hospital, Beijing"]